Logo image of RPHM

RENEO PHARMACEUTICALS INC (RPHM) Stock Fundamental Analysis

NASDAQ:RPHM - Nasdaq - US75974E1038 - Common Stock - Currency: USD

1.82  +0.09 (+5.2%)

After market: 1.81 -0.01 (-0.55%)

Fundamental Rating

3

Overall RPHM gets a fundamental rating of 3 out of 10. We evaluated RPHM against 562 industry peers in the Biotechnology industry. RPHM has a great financial health rating, but its profitability evaluates not so good. RPHM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RPHM has reported negative net income.
In the past year RPHM has reported a negative cash flow from operations.
RPHM had negative earnings in each of the past 5 years.
RPHM had a negative operating cash flow in each of the past 5 years.
RPHM Yearly Net Income VS EBIT VS OCF VS FCFRPHM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of RPHM (-71.83%) is worse than 67.25% of its industry peers.
With a Return On Equity value of -73.56%, RPHM perfoms like the industry average, outperforming 54.23% of the companies in the same industry.
Industry RankSector Rank
ROA -71.83%
ROE -73.56%
ROIC N/A
ROA(3y)-48.63%
ROA(5y)-45.99%
ROE(3y)-55.44%
ROE(5y)-52.02%
ROIC(3y)N/A
ROIC(5y)N/A
RPHM Yearly ROA, ROE, ROICRPHM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RPHM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RPHM Yearly Profit, Operating, Gross MarginsRPHM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for RPHM has been increased compared to 1 year ago.
There is no outstanding debt for RPHM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RPHM Yearly Shares OutstandingRPHM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M
RPHM Yearly Total Debt VS Total AssetsRPHM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

An Altman-Z score of 2.33 indicates that RPHM is not a great score, but indicates only limited risk for bankruptcy at the moment.
RPHM's Altman-Z score of 2.33 is fine compared to the rest of the industry. RPHM outperforms 72.54% of its industry peers.
RPHM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.33
ROIC/WACCN/A
WACCN/A
RPHM Yearly LT Debt VS Equity VS FCFRPHM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

RPHM has a Current Ratio of 57.86. This indicates that RPHM is financially healthy and has no problem in meeting its short term obligations.
RPHM has a better Current ratio (57.86) than 99.82% of its industry peers.
RPHM has a Quick Ratio of 57.86. This indicates that RPHM is financially healthy and has no problem in meeting its short term obligations.
RPHM's Quick ratio of 57.86 is amongst the best of the industry. RPHM outperforms 99.82% of its industry peers.
Industry RankSector Rank
Current Ratio 57.86
Quick Ratio 57.86
RPHM Yearly Current Assets VS Current LiabilitesRPHM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

RPHM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.78%, which is quite impressive.
EPS 1Y (TTM)27.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 33.91% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y73.79%
EPS Next 2Y33.28%
EPS Next 3Y37.16%
EPS Next 5Y33.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RPHM Yearly Revenue VS EstimatesRPHM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 200M 400M 600M
RPHM Yearly EPS VS EstimatesRPHM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RPHM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RPHM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RPHM Price Earnings VS Forward Price EarningsRPHM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RPHM Per share dataRPHM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

RPHM's earnings are expected to grow with 37.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.28%
EPS Next 3Y37.16%

More info and screens

0

5. Dividend

5.1 Amount

RPHM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RENEO PHARMACEUTICALS INC

NASDAQ:RPHM (10/4/2024, 8:00:02 PM)

After market: 1.81 -0.01 (-0.55%)

1.82

+0.09 (+5.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2024-08-13/bmo
Earnings (Next)11-06 2024-11-06/bmo
Inst Owners216.4%
Inst Owner Change0%
Ins Owners62.92%
Ins Owner Change0%
Market Cap24.28M
Analysts45.71
Price Target2.3 (26.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.5%
Min EPS beat(2)-56.86%
Max EPS beat(2)43.87%
EPS beat(4)2
Avg EPS beat(4)-7.81%
Min EPS beat(4)-56.86%
Max EPS beat(4)43.87%
EPS beat(8)5
Avg EPS beat(8)-4.28%
EPS beat(12)8
Avg EPS beat(12)0.35%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.32
P/tB 0.32
EV/EBITDA N/A
EPS(TTM)-1.69
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-4.98
FCFYN/A
OCF(TTM)-4.97
OCFYN/A
SpS0
BVpS5.76
TBVpS5.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.83%
ROE -73.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.63%
ROA(5y)-45.99%
ROE(3y)-55.44%
ROE(5y)-52.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.44%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 57.86
Quick Ratio 57.86
Altman-Z 2.33
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)306.3%
Cap/Depr(5y)200.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.38%
EPS Next Y73.79%
EPS Next 2Y33.28%
EPS Next 3Y37.16%
EPS Next 5Y33.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.63%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-62.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.21%
OCF growth 3YN/A
OCF growth 5YN/A